Analyst initiations: WL, DRH and OMRI

Posted Mar 31st 2008 11:44AM by Eric Buscemi
Filed under: Analyst Reports, Analyst Initiations

MOST NOTEWORTHY: Wilmington Trust, DiamondRock Hospitality and Omrix Biopharm were today's noteworthy initiations:

B. Riley initiated Wilmington Trust (NYSE: WL) with a Neutral rating and $33 target and points out the company has greater exposure to construction and development loans than most small- and mid-cap banks.
DiamondRock Hospitality (NYSE: DRH) was assumed with a Market perform rating and $13.50 target at Keefe Bruyette. The firm sees limited upside given expectations for continued moderation in RevPAR trends, limited operating margin expansion and an uncertain economic outlook.
Rodman & Renshaw believes that the issues that have plagued Omrix Biopharm (NASDAQ: OMRI) are now largely reflected in shares and that the company has improved visibility on business fundamentals with solid execution. The firm assumed coverage with an Outperform rating and $18 target.

OTHER INITIATIONS:

UBS initiated Millennium Pharma (NASDAQ: MLNM) with a Neutral rating and $16 target.
Credit Suisse initiated Ryanair (NASDAQ: RYAAY) with a Neutral rating.
Morgan Stanley started Brasken (NYSE: BAK) with an Underweight rating.

Tags: analyst, bak, brasken, diamondrock, downgrade, drh, millenium, mlnm, omri, omrix, ryaay, ryanair, wilmington trust, WilmingtonTrust, wl